Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC811007 dose-escalation study in type 2 diabetes mellitus and healthy adult men
ACTRN12612000261819Phase 2Completed
- Sponsor
- Protemix
- Start
- Aug 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trientine in type 2 diabetes mellitus (T2DM) (2 cohorts), sponsored by Protemix. Primary endpoint: Urinary copper excretion over 24 hours. Started Aug 2002; status: completed.
02
Drugs
trientine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12612000261819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000261819.